Japan Retracts Reports of Benefits of Hypertension Drug
A second investigation into claims of hypertension drug Valsartan’s health benefits supports recent findings that a post-market clinical trial report manipulated data and showed a significant conflict of interest.
Valsartan Clinical Trial Report
A report by the Jikei Heart Study initially stated that the hypertension drug, Valsartan, went beyond simply treating high blood pressure as patients also saw reduced risk of stroke, heart failure, and other cardiovascular complications.
Investigative committees have found, however, that substantial amounts of blood pressure data used in the report did not match patient records. The committee suggests that the manipulation occurred during the data research and was not tied to anyone from the Jikei Heart Study.
More on the Investigation into Valsartan Clinical Trial
The investigation goes on to suggest that an employee of Novartis, developer of the Valsartan, was involved in the research stage of the clinical trial. Investigators did not disclose his exact nature of his involvement, only saying it was a significant conflict of interest.
Jikei University has pulled the reports saying the clinical trial is fundamentally flawed due to the manipulated data.
Contact an Experienced Clinical Trial Attorney
Thomas J. Henry are leaders in the area of drug and product liability litigation and have represented numerous patients injured in clinical trials.
If you or a loved one have been injured in a clinical trial, contact Thomas J. Henry immediately. We represent clients/victims all over the country. We are available 24/7, nights and weekends.